Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study.
coronary artery disease
exercise test
ischemia
microvascular angina
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
28 09 2021
28 09 2021
Historique:
pubmed:
2
6
2021
medline:
29
12
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
Ischemia with no obstructive coronary artery disease (INOCA) is common and has an adverse prognosis. We set out to describe the natural history of symptoms and ischemia in INOCA. CIAO-ISCHEMIA (Changes in Ischemia and Angina over One Year in ISCHEMIA Trial Screen Failures With INOCA) was an international cohort study conducted from 2014 to 2019 involving angina assessments (Seattle Angina Questionnaire) and stress echocardiograms 1 year apart. This was an ancillary study that included patients with a history of angina who were not randomly assigned in the ISCHEMIA trial. Stress-induced wall motion abnormalities were determined by an echocardiographic core laboratory blinded to symptoms, coronary artery disease status, and test timing. Medical therapy was at the discretion of treating physicians. The primary outcome was the correlation between the changes in the Seattle Angina Questionnaire angina frequency score and changes in echocardiographic ischemia. We also analyzed predictors of 1-year changes in both angina and ischemia, and we compared CIAO participants with ISCHEMIA participants with obstructive coronary artery disease who had stress echocardiography before enrollment, as CIAO participants did. INOCA participants in CIAO were more often female (66% of 208 versus 26% of 865 ISCHEMIA participants with obstructive coronary artery disease, Improvement in ischemia and angina were common in INOCA but not correlated. Our INOCA cohort had a degree of inducible wall motion abnormalities similar to concurrently enrolled ISCHEMIA participants with obstructive coronary artery disease. Our results highlight the complex nature of INOCA pathophysiology and the multifactorial nature of angina. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02347215.
Sections du résumé
BACKGROUND
Ischemia with no obstructive coronary artery disease (INOCA) is common and has an adverse prognosis. We set out to describe the natural history of symptoms and ischemia in INOCA.
METHODS
CIAO-ISCHEMIA (Changes in Ischemia and Angina over One Year in ISCHEMIA Trial Screen Failures With INOCA) was an international cohort study conducted from 2014 to 2019 involving angina assessments (Seattle Angina Questionnaire) and stress echocardiograms 1 year apart. This was an ancillary study that included patients with a history of angina who were not randomly assigned in the ISCHEMIA trial. Stress-induced wall motion abnormalities were determined by an echocardiographic core laboratory blinded to symptoms, coronary artery disease status, and test timing. Medical therapy was at the discretion of treating physicians. The primary outcome was the correlation between the changes in the Seattle Angina Questionnaire angina frequency score and changes in echocardiographic ischemia. We also analyzed predictors of 1-year changes in both angina and ischemia, and we compared CIAO participants with ISCHEMIA participants with obstructive coronary artery disease who had stress echocardiography before enrollment, as CIAO participants did.
RESULTS
INOCA participants in CIAO were more often female (66% of 208 versus 26% of 865 ISCHEMIA participants with obstructive coronary artery disease,
CONCLUSIONS
Improvement in ischemia and angina were common in INOCA but not correlated. Our INOCA cohort had a degree of inducible wall motion abnormalities similar to concurrently enrolled ISCHEMIA participants with obstructive coronary artery disease. Our results highlight the complex nature of INOCA pathophysiology and the multifactorial nature of angina. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02347215.
Identifiants
pubmed: 34058845
doi: 10.1161/CIRCULATIONAHA.120.046791
pmc: PMC8478858
mid: NIHMS1735035
doi:
Banques de données
ClinicalTrials.gov
['NCT02347215']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1008-1023Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL119153
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105462
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105561
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105907
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL105565
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Arch Intern Med. 2009 May 11;169(9):843-50
pubmed: 19433695
Eur Heart J. 2003 Aug;24(16):1506-14
pubmed: 12919775
Eur Heart J. 2005 Oct;26(20):2136-41
pubmed: 16014645
Eur Heart J. 2011 Jun;32(11):1331-6
pubmed: 21317147
N Engl J Med. 2020 Apr 9;382(15):1395-1407
pubmed: 32227755
JAMA Cardiol. 2019 Mar 1;4(3):273-286
pubmed: 30810700
Theriogenology. 2010 Jun;73(9):1167-79
pubmed: 20138353
Eur Rev Med Pharmacol Sci. 2014;18(3):374-9
pubmed: 24563437
J Am Heart Assoc. 2017 May 4;6(5):
pubmed: 28473401
Eur Heart J. 2006 Jun;27(12):1408-15
pubmed: 16720691
Circ Cardiovasc Interv. 2019 Dec;12(12):e008126
pubmed: 31833416
Clin Cardiol. 2014 Aug;37(8):462-7
pubmed: 24719338
J Am Coll Cardiol. 2010 Jun 22;55(25):2825-32
pubmed: 20579539
J Am Coll Cardiol. 2011 Jul 26;58(5):510-9
pubmed: 21777749
Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):640-7
pubmed: 25185249
JACC Cardiovasc Interv. 2015 Sep;8(11):1445-1453
pubmed: 26404197
Circulation. 2017 Mar 14;135(11):1075-1092
pubmed: 28289007
J Am Heart Assoc. 2018 Sep 4;7(17):e008868
pubmed: 30371178
Eur Heart J. 2006 Jun;27(11):1341-81
pubmed: 16735367
Am Heart J. 2018 Jul;201:117-123
pubmed: 29772387
BMJ. 2006 Feb 4;332(7536):262-7
pubmed: 16415069
JAMA Cardiol. 2020 Jul 1;5(7):773-786
pubmed: 32227128
Am J Med Sci. 2008 May;335(5):354-62
pubmed: 18480651
J Am Soc Echocardiogr. 2020 Jan;33(1):1-41.e8
pubmed: 31740370
J Cardiol. 2008 Feb;51(1):2-17
pubmed: 18522770
Circulation. 2000 Sep 5;102(10):1193-209
pubmed: 10973852
J Am Coll Cardiol. 2013 May 21;61(20):2038-45
pubmed: 23500237
J Am Coll Cardiol. 1995 Feb;25(2):333-41
pubmed: 7829785
JAMA. 2019 Dec 17;322(23):2334-2335
pubmed: 31738820
East Afr Med J. 1969 May;46(5):220-7
pubmed: 5345960
PLoS One. 2014 Apr 04;9(4):e93170
pubmed: 24705387
Eur Heart J. 2012 Mar;33(6):734-44
pubmed: 21911339
Circulation. 2015 Mar 24;131(12):1054-60
pubmed: 25712205
Am Heart J. 2011 Oct;162(4):678-84
pubmed: 21982660
J Am Coll Cardiol. 2012 Feb 14;59(7):655-62
pubmed: 22322081
J Interv Cardiol. 2019 Mar 11;2019:7169275
pubmed: 31772544
PLoS One. 2018 Jun 8;13(6):e0196962
pubmed: 29883497
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
N Engl J Med. 2008 Aug 14;359(7):677-87
pubmed: 18703470
Circulation. 2004 Jun 22;109(24):2993-9
pubmed: 15197152
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Eur Heart J. 2018 Jun 14;39(23):2135-2146
pubmed: 29688324
Am Heart J. 2018 Jul;201:124-135
pubmed: 29778671
J Am Coll Cardiol. 2018 Nov 27;72(21):2625-2641
pubmed: 30466521
Circulation. 2008 Apr 8;117(14):1787-801
pubmed: 18378615
Circulation. 2006 Aug 29;114(9):894-904
pubmed: 16923752
J Am Coll Cardiol. 2007 Sep 18;50(12):1161-70
pubmed: 17868808